Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Astellas Pharma ( (JP:4503) ) has provided an update.
Astellas raised its FY2025 core and full-basis revenue and profit forecasts on the back of stronger-than-expected global demand for prostate cancer therapy XTANDI and overactive bladder franchise Mirabegron, amplified by favorable foreign exchange. The upgraded outlook underscores a recovery in operating leverage versus FY2024 and signals stronger cash generation for shareholders as key growth products sustain momentum in major markets.
The most recent analyst rating on (JP:4503) stock is a Buy with a Yen2556.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.
More about Astellas Pharma
Astellas Pharma is a global life sciences company developing transformative therapies in oncology, ophthalmology, urology, immunology, and women’s health, with a focus on addressing high unmet medical needs through innovative research and development.
Average Trading Volume: 8,154,166
Technical Sentiment Signal: Buy
Current Market Cap: Yen3860.8B
For an in-depth examination of 4503 stock, go to TipRanks’ Overview page.